^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    ASP1002

    i
    Other names: ASP1002, ASP 1002, ASP-1002
    Associations

    News

    Trials
    Company:
    Astellas
    Drug class:
    CD137 agonist, CLDN4 inhibitor
    Related drugs:
    Associations

    News

    Trials
    5ms
    A Study of ASP1002 in Adults for Treatment of Solid Tumors (clinicaltrials.gov)
    P1, N=210, Recruiting, Astellas Pharma Global Development, Inc. | Active, not recruiting --> Recruiting
    Enrollment open • Metastases
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    ASP1002
    8ms
    A Study of ASP1002 in Adults for Treatment of Solid Tumors (clinicaltrials.gov)
    P1, N=210, Active, not recruiting, Astellas Pharma Global Development, Inc. | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    HER-2 negative • PGR negative
    |
    ASP1002
    over1year
    A Study of ASP1002 in Adults for Treatment of Solid Tumors (clinicaltrials.gov)
    P1, N=210, Recruiting, Astellas Pharma Global Development, Inc. | Not yet recruiting --> Recruiting
    Enrollment open • Metastases
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    HER-2 negative • PGR negative
    |
    ASP1002
    almost2years
    A Study of ASP1002 in Adults for Treatment of Solid Tumors (clinicaltrials.gov)
    P1, N=210, Not yet recruiting, Astellas Pharma Global Development, Inc.
    New P1 trial • Metastases
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    HER-2 negative • PGR negative
    |
    ASP1002